Efficacy and Safety of Clopidogrel 600 mg Administered Pre-Hospitally to Improve Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction (CIPAMI): Study Rationale and Design
Authors:
- Uwe ZeymerUZUwe Zeymer
- Hans-Richard ArntzHAHans-Richard Arntz
- Harald DariusHDHarald Darius
- Kurt HuberKHKurt Huber
- Jochen SengesJSJochen Senges
- 1 November 2006
- journal article
- research article
- Published by S. Karger AG in Cardiology
- Vol. 108 (4) , 265-272
Abstract
Clopidogrel, in combination with acetylsalicylic acid, has become a mainstay of the pharmacological therapy for patients with acute coronary syndromes, especially in those undergoing percutaneous coronary interventions (PCI). While a series of studies has shown that pre-treatment with a loading dose of clopidogrel 300 or 600 mg prior to PCI is effective in reducing cardiovascular complications, the optimal dose and timing in various patient groups is still unclear. The primary objective of the present randomized, open-label Clopidogrel to Improve Primary percutaneous coronary Intervention in Acute Myocardial Infarction (CIPAMI) study is to evaluate the efficacy and the safety of a 600 mg loading dose of clopidogrel in addition to standard acetylsalicylic acid/heparin treatment in the pre-hospital setting in 654 patients with acute ST elevation myocardial infarction scheduled for primary PCI. The primary efficacy endpoint is the TIMI 2/3 patency of the infarct-related artery immediately prior to PCI. The rationale, design and methods of this study are described.Keywords
This publication has 36 references indexed in Scilit:
- ESC guidelines for percutaneous coronary interventions: replyEuropean Heart Journal, 2005
- Periodontal Disease and Coronary Heart DiseaseCirculation, 2005
- Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary InterventionCirculation, 2005
- Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion ? results of the Austrian multi-centre randomized ReoPro-BRIDGING StudyEuropean Heart Journal, 2004
- ?Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trialEuropean Heart Journal, 2004
- Adjunctive Platelet Glycoprotein IIb/IIIa Receptor Inhibition With Tirofiban Before Primary Angioplasty Improves Angiographic OutcomesCirculation, 2003
- Benefit of Clopidogrel in Patients With Acute Coronary Syndromes Without ST-Segment Elevation in Various Risk GroupsCirculation, 2002
- Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placementHeart, 2001
- Metaanalysis of five reported studies on the relation of early coronary patency grades witk mortality and outcomes after acute myocardial infarctionThe American Journal of Cardiology, 1996
- Platelet Activation in Unstable Coronary DiseaseNew England Journal of Medicine, 1986